Security Snapshot

Adagene Inc. - Ordinary shares, par value US$0.0001 per share (ADAG) Institutional Ownership

CUSIP: 005329107

13F Institutional Holders and Ownership History from Q1 2021 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

17

Shares (Excl. Options)

3,089,667

Price

$1.89

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Type / Class
Equity / Ordinary shares, par value US$0.0001 per share
Symbol
ADAG on Nasdaq
Shares outstanding
46,844,314
Price per share
$3.85
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
3,089,667
Total reported value
$6,027,495
% of total 13F portfolios
0%
Share change
-2,672,764
Value change
-$5,437,806
Number of holders
17
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • ADAG - Adagene Inc. - Ordinary shares, par value US$0.0001 per share is tracked under CUSIP 005329107.
  • 17 institutions reported positions in Q4 2025.
  • 7 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 17 to 3 between Q4 2025 and Q1 2026.
  • Reported value moved from $6,027,495 to $173,981.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 17 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 005329107?
CUSIP 005329107 identifies ADAG - Adagene Inc. - Ordinary shares, par value US$0.0001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Adagene Inc. - Ordinary shares, par value US$0.0001 per share (ADAG) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Luo Peter 16% $12,937,369 9,175,439 HAN 2020 Irrevocable Trust 25 Jan 2025
Smith Vincent C 8.7% +26% $9,120,679 +$2,258,166 5,095,351 +33% Smith Vincent C 31 Dec 2025
WuXi PharmaTech Healthcare Fund I L.P. 7% -17% $8,187,161 -$1,701,888 4,121,815 -17% WuXi PharmaTech Healthcare Fund I L.P. 30 Sep 2025
Chernett Jorey 5.1% $7,764,445 2,389,060 Chernett Jorey 16 Mar 2026
Panacea Innovation Ltd 3.8% -28% $4,469,175 -$1,564,211 2,250,000 -26% Panacea Venture Healthcare Fund II, L.P. 30 Sep 2025
FIL Ltd 1.8% -75% $1,320,902 -$4,450,930 936,810 -77% FIL Limited 31 Mar 2025
FMR LLC 0.9% $933,679 473,949 FMR LLC 30 Jun 2025

As of 31 Dec 2025, 17 institutional investors reported holding 3,089,667 shares of Adagene Inc. - Ordinary shares, par value US$0.0001 per share (ADAG). This represents 6.6% of the company’s total 46,844,314 outstanding shares.

Institutional Holders of Adagene Inc. - Ordinary shares, par value US$0.0001 per share (ADAG) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 44,383 $173,981 +$11,569 $3.92 3
2025 Q4 3,089,667 $6,027,495 -$5,437,806 $1.89 17
2025 Q3 5,722,260 $11,251,842 -$681,939 $1.99 17
2025 Q2 6,066,432 $11,842,205 -$2,692,639 $1.95 15
2025 Q1 7,596,934 $11,574,144 -$4,448,523 $1.54 13
2024 Q4 10,441,972 $20,299,608 +$6,443,398 $1.99 15
2024 Q3 11,157,880 $25,316,756 -$140,637 $2.22 13
2024 Q2 11,223,549 $33,703,166 -$3,006,648 $3.06 14
2024 Q1 12,297,346 $34,335,526 +$14,585,257 $2.80 17
2023 Q4 5,781,239 $11,163,839 -$2,205,992 $1.93 10
2023 Q3 4,096,719 $6,164,993 -$21,756 $1.53 10
2023 Q2 4,111,294 $6,016,229 -$108,766 $1.48 10
2023 Q1 4,186,071 $6,023,400 -$44,708 $1.45 11
2022 Q4 4,216,842 $5,581,186 -$2,280,668 $1.32 9
2022 Q3 5,940,279 $7,603,000 -$2,338,985 $1.28 11
2022 Q2 7,531,358 $15,421,000 -$3,922,354 $2.03 15
2022 Q1 8,391,600 $29,674,000 -$1,196,241 $3.56 15
2021 Q4 8,373,818 $67,324,000 -$5,705,274 $8.01 16
2021 Q3 8,786,888 $126,610,000 +$41,051,156 $14.37 19
2021 Q2 5,937,931 $80,519,000 -$12,766,604 $13.56 16
2021 Q1 6,435,237 $115,522,000 +$115,522,000 $17.95 27
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .